Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar

Sun, Yue-Li; Chen, Jun-Jiang; Kumar, Priyank; Chen, Kang; Sodani, Kamlesh; Patel, Atish; Chen, Yang-Lu; Chen, Si-Dong; Jiang, Wen-Qi; Chen, Zhe-Sheng
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Multidrug resistance protein 7 (MRP7, ABCC10) is a recently discovered member of the ATP-binding cassette (ABC) family which are capable of conferring resistance to a variety of anticancer drugs, including taxanes and nucleoside analogs, in vivo. MRP7 is highly expressed in non-small cell lung cancer cells, and Mrp7-KO mice are highly sensitive to paclitaxel, making MRP7 an attractive chemotherapeutic target of non-small cell lung cancer. However, only a few inhibitors of MRP7 are currently identified, with none of them having progressed to clinical trials. We used MRP7-expressing cells to investigate whether tariquidar, a third generation inhibitor of P-glycoprotein, could inhibit MRP7-mediated multidrug resistance (MDR). We found that tariquidar, at 0.1 and 0.3 µM, significantly potentiated the sensitivity of MRP7-transfected HEK293 cells to MRP7 substrates and increased the intracellular accumulation of paclitaxel. We further demonstrated that tariquidar directly impaired paclitaxel efflux and could downregulate MRP7 protein expression in a concentration- and time-dependent manner after prolonged treatment. Our findings suggest that tariquidar, at pharmacologically achievable concentrations, reverses MRP7-mediated MDR through inhibition of MRP7 protein expression and function, and thus represents a promising therapeutic agent in the clinical treatment of chemoresistant cancer patients.


Related Articles

  • New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. Westover, David; Fengzhi Li // Journal of Experimental & Clinical Cancer Research (17569966);12/30/2015, Vol. 34, p1 

    ATP-binding cassette (ABC) transporters make up a superfamily of transmembrane proteins that play a critical role in the development of drug resistance. This phenomenon is especially important in oncology, where superfamily member ABCG2 (also called BCRP – breast cancer resistance...

  • The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells. Zhonghui He; Beibei Hu; Lina Tang; Shui'er Zheng; Yuanyu Sun; Zan Sheng; Yang Yao; Feng Lin // Journal of Cancer Research & Therapeutics;Jan-Mar2015, Vol. 11 Issue 1, p18 

    Doxorubicin (Adriamycin, ADM) is an antimitotic drug used in the treatment of a wide range of malignant tumors, including acute leukemia, lymphoma, osteosarcoma, breast cancer, and lung cancer. Multidrug resistance-associated proteins (MRPs) are members of a superfamily of ATP-binding cassette...

  • Immunohistochemical study of MRP5 expression in meningiomas. Alexiou, George; Goussia, Ann; Ntoulia, Antigoni; Zagorianakou, Panagiota; Malamou-Mitsi, Vasiliki; Voulgaris, Spyridon; Kyritsis, Athanasios // Cancer Chemotherapy & Pharmacology;Mar2013, Vol. 71 Issue 3, p825 

    Purpose: Meningiomas are the most common benign intracranial tumor, accounting for 30 % of all primary intracranial tumors. Although benign meningiomas rarely recur after a complete resection, anaplastic tumors are associated with high recurrence rate and unfavorable outcome. In the current...

  • Multidrug Resistance Through the Spectacle of P-Glycoprotein. Goda, Katalin; Bacs�, Zsolt; Szab�, G�bor // Current Cancer Drug Targets;May2009, Vol. 9 Issue 3, p281 

    P-glycoprotein (Pgp), coded for by the mdr1 gene, is one of the ABC transporters held responsible for the phenomenon of multidrug resistance (mdr), which is reflected by a rapidly escalating failure of chemotherapy with different classes of cytotoxic agents: anthracyclins, vinca alkaloids,...

  • Structure of a bacterial multidrug ABC transporter. Dawson, Roger J. P.; Locher, Kaspar P. // Nature;9/14/2006, Vol. 443 Issue 7108, p180 

    Multidrug transporters of the ABC family facilitate the export of diverse cytotoxic drugs across cell membranes. This is clinically relevant, as tumour cells may become resistant to agents used in chemotherapy. To understand the molecular basis of this process, we have determined the 3.0 Ã…...

  • UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. Dongjuan Qiao; Shangjun Tang; Aslam, Sana; Ahmad, Matloob; Wah To, Kenneth Kin; Fang Wang; Zhencong Huang; Jiye Cai; Liwu Fu // American Journal of Cancer Research;2014, Vol. 4 Issue 2, p148 

    Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters through efflux of antineoplastic agents from cancer cells is a major obstacle to successful cancer chemotherapy. The inhibition of these ABC transporters is thus a logical approach to circumvent MDR. There has been...

  • Investigation of the Genes MDR1/MRP1 and Their Relationship with Clinical and Para-Clinical Characteristics of Colorectal Cancer. Samanian, Sara; Mahjoubi, Bahar; Mahjoubi, Frouzandeh; Mirzaee, Rezvan; Azizi, Rasool // Zahedan Journal of Research in Medical Sciences;Jul2013, Vol. 15 Issue 7, p31 

    Background: Resistance to wide range of structurally and functionally different chemotherapy drugs acts as a major obstacle in the cancer therapy. There are different mechanisms that cause multi drug resistance (MDR) but the most important one is ATP Binding Cassette (ABC) transporters...

  • Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors? Hegedus, Csilla; �zvegy-Laczka, Csilla; Szak�cs, Gergely; Sarkadi, Bal�zs // Current Cancer Drug Targets;May2009, Vol. 9 Issue 3, p252 

    Protein kinase inhibitors (PKI) are becoming key agents in modern cancer chemotherapy, and combination of PKIs with classical chemotherapeutic drugs may help to overcome currently untreatable metastatic cancers. Since chemotherapy resistance is a recurrent problem, mechanisms of resistance...

  • The role of ABC transporters in anticancer drug transport. KARVAR, Serhan // Turkish Journal of Biology;2014, Vol. 38 Issue 6, p800 

    The main clinical problem in cancer treatment is the development of multidrug resistance. Tumors can be intrinsically drug-resistant or develop resistance to chemotherapy. Multidrug resistance can develop by diverse mechanisms including decreased rate of drug uptake, increased drug efflux,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics